Indian captain Virat Kohli criticised his team's ability to cope under pressure after they suffered a rare series whitewash Tuesday against New Zealand following a five-wicket hammering in the third one-day international at Mount Maunganui.
A KL Rahul century was not enough of a platform for the tourists, who made 296 for seven after being put in to bat.
New Zealand, stung by a 5-0 shutout in the recent Twenty20 series, reached the target with 17 balls to spare.
A frustrated Kohli, who admonished his players for poor fielding several times during the match, said it was a fair result.
"We didn't deserve to be on the winning side at all in the series," he said.
"We haven't played so badly, but if you don't grab chances at this level then teams are going to hurt you.
"We didn't show enough composure under pressure. New Zealand did."
It was the first time India have been whitewashed in a bilateral ODI series of three or more matches since 1989 and the only time it has ever happened against New Zealand.
Openers Henry Nicholls and Martin Guptill gave the Black Caps a flying start with 80 and 66 respectively.
Colin de Grandhomme then steadied a mid-innings wobble, bludgeoning 58 off 28 balls to see the hosts finish on 300 for five.
Leg-spinner Yuzvendra Chahals was the pick of India's bowlers, taking three for 47.
Earlier, Rahul boosted India's hopes with his fourth ODI century, bringing up the landmark off 104 balls, before departing on 112.
He was supported by a gritty 62 from Shreyas Iyer but most of India's batters failed to live up to Kohli's pre-match exhortation to play positively and post a big total.
Prithvi Shaw and Manish Pandey both reached the 40s but no other batters made double figures, with Kohli out for nine.
Still, Rahul looked set to steer India to a huge total before Black Caps paceman Hamish Bennett slowed the scoring with a late flurry of wickets.
Rahul had a life on 64 when Mitchell Santner's throw at the stumps went wide and the batsman made the most of it to score his fourth ODI century, bringing up the landmark off 104 balls, including nine fours and one six.
Bennett dismissed Rahul for 112 and then snared Manish Pandey for 42 off his next ball.
His fourth wicket came when Shardul Thakur sent a full toss straight to de Grandhomme, and the bowler was unlucky not to get another when Navdeep Saini almost edged the next delivery onto his stumps.
The focus now turns to Test cricket, with the first of two five-day matches scheduled to begin in Wellington on February 21.
The results of both matches will count toward the inaugural ICC World Test Championship, in which India are runaway leaders at the top of the ladder.
Kohli said he wanted India to display an improved mentality during the Tests.
"I'm very, very excited because of the championship every match has that much more importance and we have a really good, balanced team in Test cricket," he said.
"We definitely feel we can win the series here but we obviously need to step onto the park with the right kind of mindset."
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.